Foghorn Therapeutics Inc FHTX

NAS: FHTX | ISIN: US3441741077 30/05/2025

4,080 USD (-5,56%)

(-5,56%) 30/05/2025

Grafiek Foghorn Therapeutics Inc

Grafiek Foghorn Therapeutics Inc

1 dag1d -5,56%
1 week1w 0,74%
1 maand1m -1,92%
3 maanden3m -5,56%
6 maanden6m -49,19%
1 jaar1j -34,19%
5 jaar5j -77,48%

Foghorn Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

6 augustus 2024 · Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner · Persbericht

1 november 2023 · Flagship Pioneering Launches Pioneering Intelligence · Persbericht

11 september 2023 · Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer · Persbericht

29 augustus 2023 · Invaio achieves first registration for citrus greening solution featuring Trecise™ technology · Persbericht

16 mei 2023 · Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry · Persbericht

28 februari 2022 · Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs · Persbericht

15 februari 2022 · Invaio Sciences Strengthens Its Board Of Directors With The Appointment Of Hugh Grant · Persbericht

13 december 2021 · Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform · Persbericht

13 oktober 2021 · Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change · Persbericht

25 mei 2021 · Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture · Persbericht

Profiel Foghorn Therapeutics Inc

Gezondheidstechnologie

Werknemers: 166

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe